United Therapeutics Corporation

NasdaqGS:UTHR Stock Report

Market Cap: US$14.5b

United Therapeutics Valuation

Is UTHR undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of UTHR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
US$1.01k
Fair Value
68.5% undervalued intrinsic discount
12
Number of Analysts

Below Fair Value: UTHR ($318.85) is trading below our estimate of fair value ($1012.83)

Significantly Below Fair Value: UTHR is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for UTHR?

Key metric: As UTHR is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for UTHR. This is calculated by dividing UTHR's market cap by their current earnings.
What is UTHR's PE Ratio?
PE Ratio11.9x
EarningsUS$1.21b
Market CapUS$14.45b

Price to Earnings Ratio vs Peers

How does UTHR's PE Ratio compare to its peers?

The above table shows the PE ratio for UTHR vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average23x
NBIX Neurocrine Biosciences
39.8x26.46%US$12.2b
EXEL Exelixis
18.2x18.97%US$11.6b
BMRN BioMarin Pharmaceutical
21.3x18.67%US$11.1b
BIIB Biogen
12.9x9.24%US$19.5b
UTHR United Therapeutics
11.9x7.29%US$14.5b

Price-To-Earnings vs Peers: UTHR is good value based on its Price-To-Earnings Ratio (11.9x) compared to the peer average (23x).

Price to Earnings Ratio vs Industry

How does UTHR's PE Ratio compare vs other companies in the US Biotechs Industry?

16 CompaniesPrice / EarningsEstimated GrowthMarket Cap
AGIO Agios Pharmaceuticals
2.8x-23.07%US$1.84b
NVAX Novavax
2.5x-45.35%US$1.16b
INBX Inhibrx Biosciences
0.1x-148.50%US$199.04m
CHRS Coherus BioSciences
1.8x-11.84%US$90.31m
UTHR 11.9xIndustry Avg. 15.6xNo. of Companies16PE01632486480+
16 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: UTHR is good value based on its Price-To-Earnings Ratio (11.9x) compared to the US Biotechs industry average (15.7x).

Price to Earnings Ratio vs Fair Ratio

What is UTHR's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

UTHR PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio11.9x
Fair PE Ratio19.7x

Price-To-Earnings vs Fair Ratio: UTHR is good value based on its Price-To-Earnings Ratio (11.9x) compared to the estimated Fair Price-To-Earnings Ratio (19.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst UTHR forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$318.85
US$388.18
+21.74%
19.96%US$600.00US$314.00n/a12
May ’26US$293.85
US$388.18
+32.10%
19.96%US$600.00US$314.00n/a12
Apr ’26US$306.88
US$392.22
+27.81%
18.83%US$600.00US$293.00n/a13
Mar ’26US$320.05
US$400.54
+25.15%
17.67%US$600.00US$293.00n/a13
Feb ’26US$351.17
US$402.16
+14.52%
17.75%US$600.00US$302.00n/a13
Jan ’26US$352.84
US$393.74
+11.59%
17.10%US$600.00US$302.00n/a14
Dec ’25US$370.49
US$382.22
+3.17%
20.42%US$600.00US$221.00n/a15
Nov ’25US$374.02
US$382.29
+2.21%
21.13%US$600.00US$221.00n/a14
Oct ’25US$357.83
US$356.52
-0.37%
23.14%US$575.00US$221.00n/a14
Sep ’25US$363.55
US$350.71
-3.53%
23.61%US$575.00US$221.00n/a13
Aug ’25US$327.79
US$332.79
+1.52%
15.87%US$400.00US$221.00n/a13
Jul ’25US$319.01
US$302.52
-5.17%
15.17%US$400.00US$221.00n/a14
Jun ’25US$275.13
US$294.16
+6.92%
15.54%US$400.00US$220.00n/a14
May ’25US$255.14
US$287.69
+12.76%
14.91%US$375.00US$218.00US$293.8515
Apr ’25US$228.26
US$287.33
+25.88%
16.26%US$375.00US$183.00US$306.8816
Mar ’25US$231.92
US$286.13
+23.37%
16.01%US$375.00US$183.00US$320.0516
Feb ’25US$215.97
US$284.08
+31.54%
17.27%US$375.00US$178.00US$351.1714
Jan ’25US$219.89
US$284.08
+29.19%
17.27%US$375.00US$178.00US$352.8414
Dec ’24US$240.73
US$281.88
+17.10%
17.91%US$375.00US$177.00US$370.4913
Nov ’24US$224.08
US$282.12
+25.90%
17.90%US$375.00US$177.00US$374.0213
Oct ’24US$225.87
US$278.82
+23.44%
19.95%US$375.00US$170.00US$357.8311
Sep ’24US$228.05
US$278.82
+22.26%
19.95%US$375.00US$170.00US$363.5511
Aug ’24US$240.13
US$275.73
+14.82%
21.13%US$375.00US$160.00US$327.7911
Jul ’24US$220.75
US$274.82
+24.49%
21.00%US$375.00US$160.00US$319.0111
Jun ’24US$213.48
US$275.15
+28.89%
19.31%US$375.00US$160.00US$275.1313
May ’24US$232.11
US$278.92
+20.17%
19.75%US$375.00US$150.00US$255.1413
AnalystConsensusTarget
Consensus Narrative from 12 Analysts
US$388.18
Fair Value
17.9% undervalued intrinsic discount
12
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/30 10:22
End of Day Share Price 2025/05/30 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

United Therapeutics Corporation is covered by 33 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jasper HellwegArgus Research Company
James BirchenoughBarclays
Derek TallerBenchmark Company